Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patients undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorSão Paulo State Public Servant Hospital-
Autor(es): dc.contributorDuke University School of Medicine-
Autor(es): dc.contributorScience Valley Research Institute-
Autor(es): dc.contributorAlbert Einstein Hospital-
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorMaceio-
Autor(es): dc.contributorUniversidade de São Paulo (USP)-
Autor(es): dc.contributorSanta Casa de São Paulo School of Medical Sciences-
Autor(es): dc.contributorBeneficência Portuguesa de São Paulo-
Autor(es): dc.contributorUniversidade Federal da Bahia (UFBA)-
Autor(es): dc.contributorInova Heart and Vascular Institute-
Autor(es): dc.contributorHemostasis & Thrombosis Research Laboratories at Loyola University Medical Center-
Autor(es): dc.creatorBiagioni, Rodrigo Bruno-
Autor(es): dc.creatorLopes, Renato Delascio-
Autor(es): dc.creatorAgati, Leandro Barile-
Autor(es): dc.creatorSacilotto, Roberto-
Autor(es): dc.creatorWolosker, Nelson-
Autor(es): dc.creatorSobreira, Marcone Lima [UNESP]-
Autor(es): dc.creatorde Freitas Soares, Bruno Leonardo-
Autor(es): dc.creatorJoviliano, Edwaldo Edner-
Autor(es): dc.creatorBernardi, Walkiria Hueb-
Autor(es): dc.creatorJunior, Valter Castelli-
Autor(es): dc.creatorCaffaro, Roberto Augusto-
Autor(es): dc.creatorFioranelli, Alexandre-
Autor(es): dc.creatorVan Bellen, Bonno-
Autor(es): dc.creatorCasella, Ivan Benaduce-
Autor(es): dc.creatorFidelis, Ronald José Ribeiro-
Autor(es): dc.creatorFlumignan, Ronald Luiz Gomes-
Autor(es): dc.creatorComerota, Anthony James-
Autor(es): dc.creatorRamacciotti, Eduardo-
Data de aceite: dc.date.accessioned2022-02-22T00:32:45Z-
Data de disponibilização: dc.date.available2022-02-22T00:32:45Z-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-12-11-
Data de envio: dc.date.issued2020-09-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.ahj.2020.06.010-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/201152-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/201152-
Descrição: dc.descriptionBackground: New antithrombotic strategies that reduce primary thrombosis and restenosis might improve vascular outcomes in patients with peripheral artery disease (PAD) undergoing arterial angioplasty. The study objective is to evaluate the potential benefit of apixaban plus aspirin compared with standard of care dual antiplatelet therapy (DAPT) in reducing thrombotic restenosis and artery re-occlusion in patients undergoing endovascular infrapopliteal revascularization. Study design: This multicenter, parallel-group, prospective, randomized, open-label, blinded-endpoint adjudication, proof-of-concept, exploratory trial aims to randomize 200 patients 72 hours after successful infrapopliteal angioplasty for critical limb ischemia (CLI). Patients will be randomly assigned in a 1:1 ratio to receive oral apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months or clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months. The primary endpoint is the composite of target lesion revascularization (TLR), major amputation, or restenosis/occlusion (RAS) in addition to major adverse cardiovascular events – MACE (myocardial infarction, stroke or cardiovascular death) at 12 months. The primary safety endpoint is the composite of major bleeding or clinically relevant non-major bleeding at 12 months. This study will evaluate the efficacy and safety of apixaban 2.5 mg twice daily plus aspirin compared with DAPT (clopidogrel plus aspirin) in patients with CLI undergoing endovascular infrapopliteal revascularization and might prove the concept of an alternative antithrombotic regimen for these patients to be tested in a future large randomized clinical trial.-
Descrição: dc.descriptionSão Paulo State Public Servant Hospital-
Descrição: dc.descriptionDuke Clinical Research Institute Duke University School of Medicine-
Descrição: dc.descriptionScience Valley Research Institute-
Descrição: dc.descriptionAlbert Einstein Hospital-
Descrição: dc.descriptionUniversidade Estadual Paulista (UNESP)-
Descrição: dc.descriptionSanta Casa de Maceio Maceio-
Descrição: dc.descriptionHospital das Clínicas de Ribeirão Preto São Paulo University Medical School (USP)-
Descrição: dc.descriptionSanta Casa de São Paulo School of Medical Sciences-
Descrição: dc.descriptionBeneficência Portuguesa de São Paulo-
Descrição: dc.descriptionHospital das Clínicas de São Paulo São Paulo University-
Descrição: dc.descriptionVascular and Endovascular Surgery–Federal University of Bahia-
Descrição: dc.descriptionFederal University of São Paulo-
Descrição: dc.descriptionInova Heart and Vascular Institute-
Descrição: dc.descriptionHemostasis & Thrombosis Research Laboratories at Loyola University Medical Center-
Descrição: dc.descriptionUniversidade Estadual Paulista (UNESP)-
Formato: dc.format100-106-
Idioma: dc.languageen-
Relação: dc.relationAmerican Heart Journal-
???dc.source???: dc.sourceScopus-
Título: dc.titleRationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patients undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.